NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development

Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strategy Results advance NorthStrive Biosciences' engineered probiotic platform targeting muscle preservation for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the completion of a preclinical study evaluating EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (“NorthStrive”), both...